Reducing Cardiovascular Side Effects of DMT Using Beta-Blockers.
ACS Medicinal Chemistry Letters May 8, 2025 DOI: 10.1021/acsmedchemlett.5c00180 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Descriptive study Peer reviewed |
|---|---|
| Interventions | beta-blockers nitrates |
| Topics | Psychedelic-assisted therapy DMT |
| Keywords | Cardiovascular medicine Mental health treatment Drug safety Medical research |
| Citations | 1 |
| Key points | Coformulating DMT with short-acting beta-blockers or nitrates matched to its pharmacokinetics can mitigate cardiovascular risks while preserving central therapeutic action. |
Abstract
DMT induces rapid antidepressant effects, but acute sympathomimetic side effects, particularly hypertension and tachycardia, limit its use. This study describes coformulations with short-acting beta-blockers or nitrates, matched to DMT's pharmacokinetics, to mitigate peripheral cardiovascular risks without compromising central therapeutic action, facilitating safer psychedelic therapy in vulnerable populations.
Citations in the library
Cites 4
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025
- Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cellular and Molecular Life Sciences September 10, 2024
- Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy Clinical Pharmacology & Therapeutics September 30, 2024
- Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis. Clinical Pharmacokinetics February 1, 2025